Spruce Biosciences, Inc. (SPRB) — SEC Filings
Spruce Biosciences, Inc. (SPRB) — 44 SEC filings. Latest: 8-K (Dec 15, 2025). Includes 19 8-K, 8 SC 13G/A, 5 10-Q.
View Spruce Biosciences, Inc. on SEC EDGAR
Overview
Spruce Biosciences, Inc. (SPRB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 15, 2025: Spruce Biosciences, Inc. announced on December 11, 2025, a change in its principal executive offices to 611 Gateway Boulevard, Suite 740, South San Francisco, California. This filing also indicates potential changes related to directors, officers, and compensatory arrangements, though specific detai
Sentiment Summary
Across 44 filings, the sentiment breakdown is: 1 bullish, 6 bearish, 37 neutral. The dominant filing sentiment for Spruce Biosciences, Inc. is neutral.
Filing Type Overview
Spruce Biosciences, Inc. (SPRB) has filed 19 8-K, 5 10-Q, 1 DEFA14A, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 5 SC 13D/A, 2 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (44)
Risk Profile
Risk Assessment: Of SPRB's 32 recent filings, 5 were flagged as high-risk, 19 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$16.1M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $16.387M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Barbara Fiorini
- B. Shayne Kennedy, Esq.
- B. Shayne Kennedy
Industry Context
Spruce Biosciences operates in the biotechnology sector, focusing on developing therapies for rare diseases. This industry is characterized by high R&D costs, long development timelines, significant regulatory hurdles, and intense competition for funding and market share. Companies often rely on partnerships and external financing to advance their pipelines.
Top Tags
corporate-governance (5) · delisting (4) · 10-Q (4) · regulatory-filing (4) · amendment (4) · schedule-13d (4) · listing-standards (3) · regulatory (3) · financials (3) · biotech (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Date of Report | 2025-12-11 | Earliest event reported |
| SEC File Number | 001-39594 | Spruce Biosciences' SEC filing number |
| Net Loss | $16.1M | for the six months ended June 30, 2025, indicating continued unprofitability |
| Cash Used in Operations | $21.6M | for the six months ended June 30, 2025, highlighting significant cash burn |
| Cash and Cash Equivalents | $16.4M | as of June 30, 2025, deemed insufficient to fund operations for 12 months |
| Accumulated Deficit | $266.4M | as of June 30, 2025, reflecting substantial historical losses |
| Workforce Reduction | 55% | effected on April 21, 2025, to prioritize specific product development |
| Reverse Stock Split Ratio | 1-for-75 | effective August 7, 2025, to address minimum bid price requirements |
| Collaboration Revenue | $0 | for the six months ended June 30, 2025, down from $3.612 million in 2024 |
| Workforce Reduction Expenses | $0.9M | incurred during the three months ended June 30, 2025 |
| Total Current Assets | $20.953M | as of June 30, 2025, a significant decrease from $44.206 million at December 31, 2024 |
| Total Current Liabilities | $8.060M | as of June 30, 2025, down from $15.246 million at December 31, 2024 |
| IRS Employer Identification No. | 81-2154263 | Tax identification number for Spruce Biosciences. |
| Reporting Period End | 2025-03-31 | Financials and fair value measurements are as of this date. |
| Term Loan Origination | 2019-09-30 | Date the term loan with Silicon Valley Bank was established. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Spruce Biosciences, Inc. (SPRB)?
Spruce Biosciences, Inc. has 44 recent SEC filings from Jan 2024 to Dec 2025, including 19 8-K, 8 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SPRB filings?
Across 44 filings, the sentiment breakdown is: 1 bullish, 6 bearish, 37 neutral. The dominant sentiment is neutral.
Where can I find Spruce Biosciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Spruce Biosciences, Inc. (SPRB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Spruce Biosciences, Inc.?
Key financial highlights from Spruce Biosciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SPRB?
The investment thesis for SPRB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Spruce Biosciences, Inc.?
Key executives identified across Spruce Biosciences, Inc.'s filings include Barbara Fiorini, B. Shayne Kennedy, Esq., B. Shayne Kennedy.
What are the main risk factors for Spruce Biosciences, Inc. stock?
Of SPRB's 32 assessed filings, 5 were flagged high-risk, 19 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Spruce Biosciences, Inc.?
Forward guidance and predictions for Spruce Biosciences, Inc. are extracted from SEC filings as they are enriched.